TWD 101.5
(-1.93%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -50.4 Million TWD | -390.74% |
2022 | 18.25 Million TWD | 148.95% |
2021 | -37.29 Million TWD | -2092.48% |
2020 | -1.7 Million TWD | 92.05% |
2019 | -21.39 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -6.72 Million TWD | 54.46% |
2024 Q2 | -6.72 Million TWD | 0.0% |
2023 Q2 | -10.43 Million TWD | 0.0% |
2023 Q4 | -14.76 Million TWD | 0.0% |
2023 Q1 | -10.43 Million TWD | -2848.45% |
2023 FY | -53.07 Million TWD | -390.74% |
2023 Q3 | -14.76 Million TWD | -41.45% |
2022 Q3 | -354 Thousand TWD | 0.0% |
2022 FY | 18.25 Million TWD | 148.95% |
2022 Q4 | -354 Thousand TWD | 0.0% |
2021 FY | -37.29 Million TWD | -2092.48% |
2020 FY | -1.7 Million TWD | 92.05% |
2019 FY | -21.39 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
BIONET Corp. | 84.69 Million TWD | 159.513% |
DIVA Laboratories, Ltd. | 92.15 Million TWD | 154.696% |
Genetics Generation Advancement Corp. | 18.57 Million TWD | 371.334% |
Welgene Biotech Co.,Ltd. | -4.25 Million TWD | -1083.447% |
TFBS Bioscience Inc. | -4.45 Million TWD | -1031.889% |